Who are oral mini pulse's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): fluticasone propionate hydrofluoroalkane (HFA), Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI, Oral Viscous Budesonide (OVB), palonosetron, dexamethasone, and 0.9% NaCl, peri-articular infiltration.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-mini-pulse.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

oral mini pulse — Competitive Intelligence Brief

oral mini pulse (oral mini pulse) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroids. Area: Immunology.

marketed Corticosteroids Glucocorticoid receptors Immunology Small molecule Live · refreshed every 30 min

Target snapshot

oral mini pulse (oral mini pulse) — Cairo University.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
oral mini pulse TARGET	oral mini pulse	Cairo University	marketed	Corticosteroids	Glucocorticoid receptors
fluticasone propionate hydrofluoroalkane (HFA)	fluticasone propionate hydrofluoroalkane (HFA)	Organon and Co	marketed	Inhaled corticosteroid	Glucocorticoid receptors
Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI	Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI	Orion Corporation, Orion Pharma	marketed	Combination of inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA)	Glucocorticoid receptors and β2-adrenergic receptors
Oral Viscous Budesonide (OVB)	Oral Viscous Budesonide (OVB)	Azienda Policlinico Umberto I	marketed	Corticosteroids	Glucocorticoid receptors
palonosetron, dexamethasone, and 0.9% NaCl	palonosetron, dexamethasone, and 0.9% NaCl	Sixth Affiliated Hospital, Sun Yat-sen University	phase 3	antiemetic combination	5-HT3 receptors, glucocorticoid receptors
peri-articular infiltration	peri-articular infiltration	University of Warwick	marketed	Corticosteroids and local anesthetics	Synovial membrane and surrounding soft tissues

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroids class)

Azienda Policlinico Umberto I · 1 drug in this class
Cairo University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). oral mini pulse — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-mini-pulse. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab